Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
Logo Image
|Articles|March 24, 2004

Schering extends use of Gadovist

The European Union has approved the use of Schering's extracellular agent Gadovist 1.0 for use in MR angiography. Gadovist 1.0 previously had been cleared for contrast-enhanced MR of the brain and spine by EU members and other countries, including the

The European Union has approved the use of Schering's extracellular agent Gadovist 1.0 for use in MR angiography. Gadovist 1.0 previously had been cleared for contrast-enhanced MR of the brain and spine by EU members and other countries, including the U.S. It is the first extracellular contrast agent to receive EU approval for this indication.

Related to this article

View more
Key Sessions of Interest for Radiologists at the Upcoming HLTH USA Conference
Key Sessions of Interest for Radiologists at the Upcoming HLTH USA Conference
How will generative AI software be evaluated by the FDA in the future? What’s next for point-of-care ultrasound? What steps have been successful in facilitating adoption of AI applications across enterprise systems? Leaders in radiology and health care will be discussing these topics and more at the upcoming HLTH USA conference.
Read more